| 1 |
34312098 | Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients. | 2022 Jan |
2 |
| 2 |
33622356 | Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china. | 2021 Feb 23 |
1 |
| 3 |
33685057 | [Docetaxel, carboplatin plus trastuzumab as neoadjuvant setting in patients with early-stage human epidermal growth factor receptor 2 positive breast cancer: a retrospective analysis]. | 2021 Mar 1 |
1 |
| 4 |
33959195 | Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial. | 2021 |
2 |
| 5 |
34168999 | Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer. | 2021 |
2 |
| 6 |
34533681 | Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer. | 2021 Dec |
1 |
| 7 |
29205665 | Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo-adjuvant treatment for Her2 positive breast cancer patients and impact of colony-stimulating factor prophylaxis. | 2018 Jul |
2 |
| 8 |
29665663 | [Analysis of neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) in HER-2-positive breast cancer]. | 2018 Mar 27 |
3 |
| 9 |
30071039 | Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH). | 2018 |
1 |
| 10 |
30275685 | Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer. | 2018 |
1 |
| 11 |
28040858 | Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer. | 2017 Feb |
1 |
| 12 |
27920624 | Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years. | 2016 Oct |
1 |
| 13 |
25789069 | Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer. | 2015 Apr |
2 |
| 14 |
22065290 | Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. | 2012 Jan |
1 |
| 15 |
22349922 | A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancers. | 2012 May |
3 |
| 16 |
28497437 | FDA Approves TCH Combination for HER2-Positive Early Breast Cancer. | 2008 Jun 1 |
1 |